+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Antibody Drug Conjugates (ADC) - Global Strategic Business Report

  • PDF Icon

    Report

  • 193 Pages
  • November 2024
  • Region: Global
  • Global Industry Analysts, Inc
  • ID: 6018388
The global market for Antibody Drug Conjugates (ADC) was estimated at US$9.4 Billion in 2023 and is projected to reach US$23.2 Billion by 2030, growing at a CAGR of 13.8% from 2023 to 2030. This comprehensive report provides an in-depth analysis of market trends, drivers, and forecasts, helping you make informed business decisions.

Global Antibody Drug Conjugates (ADC) Market - Key Trends and Drivers Summarized

What Are Antibody Drug Conjugates and How Are They Revolutionizing Cancer Treatment?

Antibody Drug Conjugates (ADCs) are a cutting-edge class of biopharmaceuticals designed to target and treat cancer with high precision. ADCs combine the targeting ability of monoclonal antibodies with potent cytotoxic drugs, enabling them to deliver chemotherapeutic agents directly to cancer cells while minimizing damage to healthy tissues. This targeted approach has made ADCs an increasingly attractive option in oncology, especially for cancers that have proven resistant to traditional treatments. By utilizing monoclonal antibodies that bind to specific proteins on the surface of cancer cells, ADCs can deliver toxic payloads more efficiently, enhancing therapeutic outcomes while reducing systemic side effects. ADCs are used in the treatment of various cancers, including breast cancer, lymphomas, and solid tumors.

How Is the ADC Market Segmented and What Are the Key Applications?

Technologically, the market is divided into types of linkers and payloads used, which are critical components in ensuring the drug's stability and efficacy. In terms of application, breast cancer currently dominates the ADC market, given the high success rate of treatments like Kadcyla and Enhertu. Other target indications include hematologic malignancies and solid tumors, with ongoing clinical trials aiming to expand the use of ADCs to more cancer types. End-users primarily include hospitals, oncology clinics, and cancer research institutes, where ADCs are administered as part of comprehensive cancer treatment regimens. North America leads the market due to its advanced healthcare infrastructure and high investment in oncology research, while Europe and Asia-Pacific are emerging as key regions due to increasing healthcare expenditures and cancer prevalence.

How Are Technological Innovations Impacting the ADC Market?

Technological advancements are playing a pivotal role in the growth and effectiveness of ADCs. Innovations in linker chemistry have improved the stability and precision of ADCs, enabling better drug release at the cancer site and reducing off-target toxicity. Advances in cytotoxic payloads are also enhancing the potency of ADCs, making them more effective against drug-resistant cancer cells. Moreover, ongoing research in identifying new cancer biomarkers is expanding the potential applications of ADCs beyond current use cases, allowing for the development of next-generation ADCs that target previously untreatable cancers. Regulatory agencies like the FDA are also expediting approvals for new ADC therapies, recognizing their potential to transform cancer treatment.

What Factors Are Driving the Growth in the Antibody Drug Conjugates Market?

The growth in the Antibody Drug Conjugates (ADC) market is driven by several factors, including the increasing prevalence of cancer and the demand for more targeted, effective treatments. The advancements in linker technologies and payload delivery systems have enhanced the efficacy and safety profile of ADCs, contributing to their growing adoption in oncology. Furthermore, the rise in personalized medicine, where treatments are tailored to individual patients based on genetic and molecular markers, is propelling the development of ADCs. Clinical success and the approval of leading ADC products have spurred further investment in R&D, expanding the pipeline for future ADC therapies. Additionally, growing awareness and demand for therapies with fewer side effects compared to traditional chemotherapy are further driving market growth.

Key Insights:

  • Market Growth: Understand the significant growth trajectory of the Breast Cancer End-Use segment, which is expected to reach US$11.0 Billion by 2030 with a CAGR of a 14.5%. The Blood Cancer End-Use segment is also set to grow at 13.4% CAGR over the analysis period.
  • Regional Analysis: Gain insights into the U.S. market, which was estimated at $2.6 Billion in 2023, and China, forecasted to grow at an impressive 18.5% CAGR to reach $5.2 Billion by 2030. Discover growth trends in other key regions, including Japan, Canada, Germany, and the Asia-Pacific.

Why You Should Buy This Report:

  • Detailed Market Analysis: Access a thorough analysis of the Global Antibody Drug Conjugates (ADC) Market, covering all major geographic regions and market segments.
  • Competitive Insights: Get an overview of the competitive landscape, including the market presence of major players across different geographies.
  • Future Trends and Drivers: Understand the key trends and drivers shaping the future of the Global Antibody Drug Conjugates (ADC) Market.
  • Actionable Insights: Benefit from actionable insights that can help you identify new revenue opportunities and make strategic business decisions.

Key Questions Answered:

  • How is the Global Antibody Drug Conjugates (ADC) Market expected to evolve by 2030?
  • What are the main drivers and restraints affecting the market?
  • Which market segments will grow the most over the forecast period?
  • How will market shares for different regions and segments change by 2030?
  • Who are the leading players in the market, and what are their prospects?

Report Features:

  • Comprehensive Market Data: Independent analysis of annual sales and market forecasts in US$ Million from 2023 to 2030.
  • In-Depth Regional Analysis: Detailed insights into key markets, including the U.S., China, Japan, Canada, Europe, Asia-Pacific, Latin America, Middle East, and Africa.
  • Company Profiles: Coverage of major players in the Antibody Drug Conjugates (ADC) market such as ADC Therapeutics SA, Astellas Pharma, Inc., AstraZeneca Plc, Daiichi Sankyo Co., Ltd., Enzo Biochem, Inc. and more.
  • Complimentary Updates: Receive free report updates for one year to keep you informed of the latest market developments.

Some of the 52 companies featured in this Antibody Drug Conjugates (ADC) market report include:

  • ADC Therapeutics SA
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co., Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • ImmunoGen, Inc.
  • MabPlex International

Table of Contents

I. METHODOLOGYII. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Impact of COVID-19 and a Looming Global Recession
  • Antibody Drug Conjugates (ADC) - Global Key Competitors Percentage Market Share in 2024 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
  • Rising Prevalence of Cancer Drives Demand for Targeted Therapeutic Solutions
  • Technological Advancements in Biopharmaceuticals Propel Growth of ADC Market
  • Expansion of Precision Medicine Strengthens Business Case for Antibody Drug Conjugates
  • Rising Focus on Immuno-Oncology Fuels Innovation in ADC Development
  • Advancements in Targeted Drug Delivery Systems Propel Growth of ADC Therapies
  • Expanding Use of ADCs in Hematologic Malignancies Drives Market Demand
  • Rising Interest in Combination Therapies Strengthens Adoption of ADCs in Cancer Treatment
  • Increasing Focus on Personalized Medicine Expands Addressable Market for ADC-Based Therapies
  • Growing Awareness of Precision Therapeutics Sustains Demand for Targeted Cancer Therapies
  • Advancements in Payload and Linker Technologies Generate Opportunities for Innovative ADC Products
  • Rising Prevalence of Chronic Diseases Beyond Cancer Expands Applications of ADCs
4. GLOBAL MARKET PERSPECTIVE
  • Table 1: World Antibody Drug Conjugates (ADC) Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • Table 2: World Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 3: World Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 4: World 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2024 & 2030
  • Table 5: World Recent Past, Current & Future Analysis for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 6: World Historic Review for Breast Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 7: World 16-Year Perspective for Breast Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 8: World Recent Past, Current & Future Analysis for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 9: World Historic Review for Blood Cancer End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 10: World 16-Year Perspective for Blood Cancer End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
  • Table 11: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 12: World Historic Review for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 13: World 16-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2024 & 2030
III. MARKET ANALYSIS
UNITED STATES
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
  • Table 14: USA Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 15: USA Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 16: USA 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
CANADA
  • Table 17: Canada Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 18: Canada Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 19: Canada 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
JAPAN
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
  • Table 20: Japan Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 21: Japan Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 22: Japan 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
CHINA
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
  • Table 23: China Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 24: China Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 25: China 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
EUROPE
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
  • Table 26: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 27: Europe Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 28: Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2024 & 2030
  • Table 29: Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 30: Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 31: Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
FRANCE
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
  • Table 32: France Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 33: France Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 34: France 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
GERMANY
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
  • Table 35: Germany Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 36: Germany Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 37: Germany 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
ITALY
  • Table 38: Italy Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 39: Italy Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 40: Italy 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
UNITED KINGDOM
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
  • Table 41: UK Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 42: UK Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 43: UK 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
SPAIN
  • Table 44: Spain Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 45: Spain Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 46: Spain 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
RUSSIA
  • Table 47: Russia Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 48: Russia Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 49: Russia 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
REST OF EUROPE
  • Table 50: Rest of Europe Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 51: Rest of Europe Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 52: Rest of Europe 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
ASIA-PACIFIC
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
  • Table 53: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
  • Table 54: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 55: Asia-Pacific 16-Year Perspective for Antibody Drug Conjugates (ADC) by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2024 & 2030
  • Table 56: Asia-Pacific Recent Past, Current & Future Analysis for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
  • Table 57: Asia-Pacific Historic Review for Antibody Drug Conjugates (ADC) by End-Use - Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
  • Table 58: Asia-Pacific 16-Year Perspective for Antibody Drug Conjugates (ADC) by End-Use - Percentage Breakdown of Value Sales for Breast Cancer End-Use, Blood Cancer End-Use and Other End-Uses for the Years 2014, 2024 & 2030
AUSTRALIA
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2024 (E)
INDIA
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2024 (E)
SOUTH KOREAREST OF ASIA-PACIFIC
LATIN AMERICA
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2024 (E)
ARGENTINABRAZILMEXICOREST OF LATIN AMERICA
MIDDLE EAST
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2024 (E)
IRANISRAELSAUDI ARABIAUNITED ARAB EMIRATESREST OF MIDDLE EAST
AFRICA
  • Antibody Drug Conjugates (ADC) Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2024 (E)
IV. COMPETITION

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

  • ADC Therapeutics SA
  • Astellas Pharma, Inc.
  • AstraZeneca Plc
  • Daiichi Sankyo Co., Ltd.
  • Enzo Biochem, Inc.
  • F. Hoffmann-La Roche AG
  • Gilead Sciences, Inc.
  • GSK Plc
  • ImmunoGen, Inc.
  • MabPlex International

Table Information